4D Molecular Therapeutics, Inc. (FDMT) vs Prime Medicine, Inc. (PRME)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Prime Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.76HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
PRME
Prime Medicine, Inc.
$3.49HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — FDMT vs PRME
growth of $100 · dividends reinvested · last 4yFDMT +86.4% (+16.9%/yr)PRME -79.1% (-32.4%/yr)FDMT compounded faster over this window
Log scale — wide-divergence pair
FDMT PRME
FDMT vs PRME: by the numbers
- •FDMT is the larger company ($667M vs $629M market cap).
- •Both run net losses; FDMT's is the smaller (-194.74% vs -4613.11% net margin).
- •FDMT grew revenue faster over the past five years (31.93% vs -2.32% CAGR).
Metrics side by side
Valuation
| Metric | FDMT | PRME |
|---|---|---|
| P/S ratio | 7.25 | 154.54 |
| P/B ratio | 1.64 | 15.81 |
Profitability
| Metric | FDMT | PRME |
|---|---|---|
| Gross margin | 91.05% | -58.05% |
| Operating margin | -187.24% | -4498.06% |
| Net margin | -194.74% | -4613.11% |
| ROE | -43.95% | -471.98% |
| ROIC | -44.30% | -90.42% |
Growth (annualized)
| Metric | FDMT | PRME |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | -2.32% |
| Total return CAGR (5Y) | -13.08% | N/A |
Frequently asked
- Which has grown faster, FDMT or PRME?
- Over the past five years, FDMT grew revenue faster — FDMT at a 31.93% CAGR versus PRME at -2.32%.
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROEPrime Medicine ROE4D Molecular Therapeutics operating marginPrime Medicine operating margin4D Molecular Therapeutics revenue growthPrime Medicine revenue growth4D Molecular Therapeutics free cash flowPrime Medicine free cash flow
4D Molecular Therapeutics & Prime Medicine appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.